Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

This Research Topic seeks original research, reviews, and meta-analyses on topics such as strategic nanocomplex-mediated modulation of the tumor microenvironment, novel smart nanocomplexes with ...

Sustained Immunomodulation: SAB-142 demonstrated a clinically validated multi-target MOA with sustained immunomodulation. MoA ...

SAB BIO (NASDAQ:SABS) released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy ...

NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market capitalization of $87 million, has announced promising preclinical results for ...

Sustained Immunomodulation: SAB-142 demonstrated a clinically validated multi-target MOA with sustained immunomodulation. MoA Analogous to Rabbit ATG: The mechanism of action (MoA) of SAB-142 ...

More than 40 researchers from across the country will work with NYU Langone Health and the NYU Grossman School of Medicine as ...

This Review discusses the targets and mechanisms of MSC-mediated immunomodulation and the possible translation of MSCs to new therapeutic approaches. MSCs that are cultured in vitro lack specific ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Following on from its news yesterday of the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab, the Company ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...